Bioverativ - 500 Beiträge pro Seite

[R-BgO]

ist ein spin-off von Biogen:


Biogen Completes Separation of Global Hemophilia Business, Bioverativ
– Bioverativ Common Stock to Be Traded on The NASDAQ Global Select Market –


Wednesday, February 1, 2017 7:30 am EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Biogen Inc. (NASDAQ: BIIB) today announced the completion on February 1, 2017 of the separation of its global hemophilia business. The new company, known as Bioverativ, is an independent, publicly traded global biotechnology company focused on hemophilia and other rare blood disorders. Bioverativ common stock will begin “regular way” trading on Thursday, February 2, 2017, under the symbol “BIVV” on the NASDAQ Global Select Market.

On December 20, 2016, Biogen announced that its board of directors approved the separation of Biogen and Bioverativ, and declared a special dividend distribution of one share of Bioverativ common stock for every two shares of Biogen common stock held as of the close of business on January 17, 2017, the record date for the distribution.

As previously announced, Biogen’s common stock trades on the NASDAQ Global Select Market in the “regular way” under the symbol "BIIB" and in the "ex-distribution" market under the symbol "BIIBV.” Biogen stockholders who have sold their shares of Biogen common stock in the regular way market after January 17, 2017, the record date for the distribution, and on or prior to February 1, 2017, will have sold their right to receive shares of Bioverativ common stock in the distribution. Shares of Biogen common stock in the "ex-distribution" market trade without the right to receive shares of Bioverativ common stock in the distribution.

[R-BgO]

Antwort auf Beitrag Nr.: 54.267.104 von R-BgO am 08.02.17 10:00:58

meine Stücke

wurden heute eingebucht

[kainza]

Antwort auf Beitrag Nr.: 54.267.104 von R-BgO am 08.02.17 10:00:58

In welchem Verhältnis erfolgte der Spin-Off?
Bzw. um wie viel Euro wurde Biogen dadurch "leichter"?

[R-BgO]

Antwort auf Beitrag Nr.: 55.020.630 von kainza am 26.05.17 09:47:17

Lesen!

aus #1: "declared a special dividend distribution of one share of Bioverativ common stock for every two shares of Biogen common stock "

[kainza]

Antwort auf Beitrag Nr.: 55.021.113 von R-BgO am 26.05.17 10:43:31

Also ein Abschlag von ca. 25 Euro pro Biogenaktie?

Wie schätzt du den Spin-off-Wert ein?

[R-BgO]

Antwort auf Beitrag Nr.: 54.267.110 von R-BgO am 08.02.17 10:01:35

kurzes Vergnügen;

...sie werden gekauft:


Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
Sudip Kar-Gupta

PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, in a deal which it said would boost earnings and strengthen its presence in treatments for rare diseases.

The move comes at a time of renewed interest by large drugmakers in smaller biotech firms and predictions by some experts that 2018 will see a substantial pick-up in mergers and acquisitions.

Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $105 per share in cash, marking a premium of 64 percent to Bioverativ’s closing price on January 19.

Bioverativ, a maker of haemophilia drugs, was separated from Biogen Inc early last year.

The agreed transaction marks Sanofi’s successful return to deal-making after its failure to land major takeovers in recent years. It is its biggest acquisition since the 2011 takeover of U.S. biotech company Genzyme for around $20 billion.

[R-BgO]

Antwort auf Beitrag Nr.: 56.786.131 von R-BgO am 22.01.18 09:51:51

Ausbuchung

kam im April